The combination of casirivimab and imdevimab is an investigational drug product being studied in the US and Canada to treat coronavirus disease, also known as COVID-19. In the US, this product is not FDA-approved; however, it is FDA-authorized for emergency use to treat COVID-19. It is used by people over the age of 12 who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 10 days, and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). In Canada, the combination of casirivimab and imdevimab has not yet been authorized by Health Canada for emergency or conditional use. Talk to your doctor about the risks and benefits of treatment with casirivimab and imdevimab.Casirivimab and imdevimab are antibodies which, when given soon after infection, can neutralize the coronavirus and may prevent worsening of COVID-19 symptoms. More information about casirivimab and imdevimab is available from the FDA Fact Sheet for Patients, Parents and Caregivers for Emergency Use, or should be provided by the doctor from the Informed Consent Form for a study.There is limited information about how safe and effective the combination of casirivimab and imdevimab is for treating COVID-19. Study results show that casirivimab and imdevimab may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19, or who need supplemental oxygen or a ventilator due to COVID-19.The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of casirivimab and imdevimab, and it is always the responsibility of treating practitioners to exercise independent judgment in making care decisions.

How to use Casirivimab 120 Mg/Ml-Imdevimab Mg/Ml Intravenous Solution (EUA)

The combination of casirivimab and imdevimab is given one time by injection into a vein by a healthcare professional. It is infused over at least one hour. A healthcare professional will observe you during your infusion and for at least another hour after your treatment in case you have serious side effects.

Drug Survey

Are you currently using Casirivimab 120 Mg/Ml-Imdevimab Mg/Ml Intravenous Solution (EUA)?

This survey is being conducted by the WebMD marketing sciences department.

Free RX Coupon

Save up to 80% on your prescriptions.

Available coupons

Save up to 80% on your prescription with WebMDRx

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.